CHM chimeric therapeutics limited

Ann: AML patient achieves Complete Response in CHM CORE-NK trial, page-57

  1. 8,329 Posts.
    lightbulb Created with Sketch. 3661
    It's interesting what ChatGPT puts forth about combining CORE-NK and Pomalidomide with Vactrosertib and its potential significance for solid tumours.

    This is the area where CHM is being positioned within the immunotherapy space. Merck's patent for Keytruda runs out in 2028. The cost of treating the side effects of chemo is a real burden to economies. There is likely never going to be a blockbuster miracle cure for cancer but immunotherapy will give patients quality of life while being treated with the right combo of therapies.

    https://hotcopper.com.au/data/attachments/6525/6525810-6775e246da7a41207967c75f52bf6775.jpg
    https://hotcopper.com.au/data/attachments/6525/6525814-1e6fd058b7f1b8673b8a975574992ad5.jpg


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $100 25K

Buyers (Bids)

No. Vol. Price($)
28 21874000 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 19510638 27
View Market Depth
Last trade - 15.25pm 17/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.